AG
CYTK icon

Ascent Group’s Cytokinetics CYTK Stock Holding History

Ascent Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
+2,908
New +$209K 0.01% 718
2026
Q1 		– Sell
-3,149
Closed -$200K – 764
2025
Q4 		$200K Buy
+3,149
New +$196K 0.01% 724

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ascent Group's CYTK Position: Q2 2026 in Review

Ascent Group opened a new position in Cytokinetics (CYTK) in Q2 2026: 2,908 shares worth $248K. The stake represents 0.01% of the portfolio and ranks #718 among its holdings. This is a return to the name: Ascent Group previously reported a position in CYTK as recently as Q4 2025.

Ascent Group first reported a position in CYTK in Q4 2025 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Ascent Group held 2,908 shares of Cytokinetics worth $248K as of Q2 2026.
  • Cytokinetics was a new Ascent Group position in Q2 2026.
  • Cytokinetics made up 0.01% of Ascent Group's portfolio in Q2 2026, its #718 holding.
  • Ascent Group first reported a position in Cytokinetics in Q4 2025 and has held it in 2 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.